Modeling Data Supports Cologuard Use Every Three Years
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Jefferies Cuts Price Target on Exact Sciences (EXAS) Following Disappointing Outlook
February 25, 2016 9:29 AM ESTJefferies maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target to $13.00 (from $15.00), following the company's 4Q. . In light of the 4Q test volume shortfall, EXAS' initial outlook for flattish trends in 1Q16 was disappointing. EXAS reaffirmed its '16 revenue... More
